Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Although statins reduce cardiovascular events, residual risk remains. Therefore, additional modalities are needed to reduce risk. We evaluated the effect of eicosapentaenoic acid and docosahexaenoic acid in pharmacologic doses added to statin treatment on coronary artery plaque volume. Methods and Results: A total of 285 subjects with stable coronary artery disease on statins were randomized to omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily) or no omega‐3 (control) for 30 months. Coronary plaque volume was assessed by coronary computed tomographic angiography. Mean ( SD ) age was 63.0 (7.7) years; mean low‐density lipoprotein cholesterol ≤80 mg/dL. In the intention‐to‐treat analysis, our primary endpoint, noncalcified plaque volume, was not different between groups ( P =0.14) but approached significance in the per protocol analysis ( P =0.07). When stratified by age in the intention‐to‐treat analysis, younger omega‐3 subjects had significantly less progression of the primary endpoint, noncalcified plaque ( P =0.013), and fibrous, calcified and total plaque. In plaque subtype analysis, controls had significant progression of fibrous plaque compared to no change in the omega‐3 ethyl‐ester group (median % change [interquartile range], 5.0% [−5.7, 20.0] versus −0.1% [−12.3, 14.5], respectively; P =0.018). Among those on low‐intensity statins, omega‐3 ethyl‐ester subjects had attenuation of fibrous plaque progression compared to controls (median % change [interquartile range], 0.3% [−12.8, 9.0] versus 4.8% [−5.1, 19.0], respectively; P =0.032). In contrast, those on high‐intensity statins had no difference in plaque change in either treatment arm. Conclusions: High‐dose eicosapentaenoic acid and docosahexaenoic acid provided additional benefit to statins in preventing progression of fibrous coronary plaque in subjects adherent to therapy with well‐controlled low‐density lipoprotein cholesterol levels. The benefit on low‐intensity statin, but not high‐intensity statin, suggests that statin intensity affects plaque volume. Clinical Trial Registration: URL : http://www.ClinicalTrials.gov . Unique identifier: NCT 01624727.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 3×
“nonphlogistic infiltration of monocytes, which differentiate into resolution macrophages.(33) These resolution macrophages then phagocytize and clear apoptotic neutrophils and debris, a process termed efferocytosis, which is a key step in resolution and prevention of chronic inflammation.”
BackgroundResolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · cited 1×
“Elevated levels of triglyceride are associated with increasing risk of coronary heart disease.(26) As expected, triglyceride levels were significantly reduced in the omega-3 ethyl-ester group compared with the control group.”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
Nicholls, S. J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.026 · Cited by 475
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Coronary Atherosclerosis Imaging by Coronary CT Angiography
Voros, S., Rinehart, S., Qian, Z., Joshi, P., Vazquez, G., Fischer, C., Belur, P., Hulten, E., & Villines, T. C. (2011) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2011.03.006 · Cited by 362
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284 · cited 1×
“In past studies, DHA raised LDL-C levels whereas EPA did not.(50,51) In the current study of EPA plus DHA, there was no difference in LDL-C levels in the omega-3 versus no omega-3 groups; therefore, high-dose EPA plus DHA had no effect on LDL-C.”
BackgroundMas, E., Croft, K. D., Zahra, P., Barden, A., & Mori, T. A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.190199 · Cited by 270
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263 · cited 1×
“In past studies, DHA raised LDL-C levels whereas EPA did not.(50,51) In the current study of EPA plus DHA, there was no difference in LDL-C levels in the omega-3 versus no omega-3 groups; therefore, high-dose EPA plus DHA had no effect on LDL-C.”
BackgroundWatanabe, T., Ando, K., Daidoji, H., Otaki, Y., Sugawara, S., Matsui, M., Ikeno, E., Hirono, O., Miyawaki, H., Yashiro, Y., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.007 · Cited by 177
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K. (2016) · The FASEB Journal · doi:10.1096/fj.201500155r · Cited by 143 · cited 1×
“In a subset of 6 patients from the current study, several resolvins, which have been shown to be present in healthy subjects, were absent or present at low levels in CAD patients not on omega3 ethyl-ester; the resolvins were restored or their level increased in those receiving omega-3 ethyl-ester.(39) The stimulation…”
BackgroundSelf-citationNiki, T., Wakatsuki, T., Yamaguchi, K., Taketani, Y., Oeduka, H., Kusunose, K., Ise, T., Iwase, T., Yamada, H., Soeki, T., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-0813 · Cited by 83 · cited 1×
“Two studies in Japanese patients have shown a significant additional benefit of EPA (1800 mg/ day) added to statin therapy compared with statin alone on coronary plaque volume, as measured with integrated backscatter intravascular ultrasound.(44,45) In a post-hoc analysis of 50 diabetics who were randomized to pravast…”
Method
Cited by
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 630
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Khan, S. U., Lone, A. N., Khan, M. S., Virani, S. S., Blumenthal, R. S., Nasir, K., Miller, M., Michos, E. D., Ballantyne, C. M., Boden, W. E., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100997 · Cited by 411
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., Summerbell, C. D., Worthington, H. V., Song, F., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub5 · Cited by 295
EPA and DHA containing phospholipids have contrasting effects on membrane structure
Sherratt, S. C. R., Juliano, R. A., Copland, C., Bhatt, D. L., Libby, P., & Mason, R. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100106 · Cited by 92
Metadata
- Authors
- Alfaddagh, A., Elajami, T. K., Ashfaque, H., Saleh, M., Bistrian, B. R., & Welty, F. K.
- Venue
- Journal of the American Heart Association
- Published
- 2017-12-02
- Volume
- 6
- Issue
- 12
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2773247353
- Cited by
- 94
- References
- 19
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.